Safety of azithromycin in paediatrics: a systematic review protocol by Xu, Peipei et al.
1Xu P, et al. BMJ Paediatrics Open 2019;3:e000469. doi:10.1136/bmjpo-2019-000469
Open access 
Safety of azithromycin in paediatrics: a 
systematic review protocol
Peipei Xu,   1,2,3,4 Linan Zeng,1,2,4 Tao Xiong,   5 Imti Choonara,   6 Shamim Qazi,7 
Lingli Zhang1,2,4 
To cite: Xu P, Zeng L, Xiong T, 
et al. Safety of azithromycin in 
paediatrics: a systematic review 
protocol. BMJ Paediatrics Open 
2019;3:e000469. doi:10.1136/
bmjpo-2019-000469
 ► Additional material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
bmjpo- 2019- 000469).
Received 18 February 2019
Revised 2 April 2019
Accepted 3 April 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Lingli Zhang;  zhanglingli@ 
scu. edu. cn
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
What is already known on this topic?
 ► Azithromycin is a widely used antibiotic in children.
 ► It is used for individual patients and as mass drug 
administration for controlling a few infectious 
diseases.
 ► Diarrhoea, nausea and vomiting are the most com-
mon side effects of azithromycin.
What this study hopes to add?
 ► The most frequent adverse drug reactions of 
azithromycin in children following mass drug 
administration.
 ► The likelihood of significant drug toxicity with azith-
romycin in children.
AbstrACt
Introduction Azithromycin is widely used in children not 
only in the treatment of individual children with infectious 
diseases, but also as mass drug administration (MDA) 
within a community to eradicate or control specific tropical 
diseases. MDA has also been reported to have a beneficial 
effect on child mortality and morbidity. However, concerns 
have been raised about the safety of azithromycin, 
especially in young children. The aim of this review is 
to systematically identify the safety of azithromycin in 
children of all ages.
Methods and analysis MEDLINE, PubMed, Cochrane 
Central Register of Controlled Trials, Embase, CINAHL, 
International Pharmaceutical Abstracts and adverse drug 
reaction (ADR) monitoring systems will be systematically 
searched for randomised controlled trials (RCTs), cohort 
studies, case–control studies, cross-sectional studies, 
case series and case reports evaluating the safety of 
azithromycin in children. The Cochrane risk of bias tool, 
Newcastle-Ottawa and quality assessment tools, and The 
Joanna Briggs Institute Critical Appraisal tools will be used 
for quality assessment. Meta-analyses will be conducted 
to the incidence of ADRs from RCTs if appropriate. 
Subgroup analyses will be performed in different age and 
azithromycin dosage groups.
Ethics and dissemination Formal ethical approval is not 
required as no primary data are collected. This systematic 
review will be disseminated through a peer-reviewed 
publication.
PrOsPErO registration number CRD42018112629
IntrOduCtIOn
Azithromycin is a macrolide antibiotic that 
has a structure modified from erythromycin. 
Like other macrolides, azithromycin is active 
against Streptococcus pneumoniae and Moraxella 
catarrhalis and is active against atypical path-
ogens, such as Mycoplasma pneumoniae, Chla-
mydia pneumoniae and Legionella pneumophila.1 
In 2010, azithromycin was the most prescribed 
antibiotic for adult outpatients in the USA.2 It 
is one of the most commonly prescribed anti-
biotics in children with a prescription rate of 
between 4% and 14%, which has been used 
extensively for the treatment of several paedi-
atric infectious diseases.3–6 It is effective in 
respiratory infections, which are common in 
children.
The WHO recommends 3–5 years of annual 
mass azithromycin distribution (MDA) to 
control trachoma in communities with >10% 
follicular trachoma prevalence among chil-
dren aged 1–9 years.7 MDA is also used for 
other infectious diseases in selected circum-
stances. Some recent evidence suggests that 
postneonatal infant and child mortality can 
be reduced in some contexts, by providing 
azithromycin periodically to all children 
aged 1–59 months, through an MDA plat-
form.8–10 The generalisability of the findings 
is, however, unclear and there is a concern 
about increasing antimicrobial resistance and 
other possible adverse consequences if azith-
romycin MDA was implemented on a wider 
scale.11
Owing to the lack of safety studies, azith-
romycin is not recommended for children 
aged less than 6 months for oral formula-
tions and 16 years for intravenous formula-
tions.12 13 Abdominal discomforts, such as 
diarrhoea, nausea and vomiting, are the most 
commonly reported side effects in paediat-
rics.12 Recent studies have yielded conﬂicting 
information about the cardiovascular safety 
of azithromycin.14–16 But these studies 
most likely reached different conclusions 
because they involved patients with different 
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characteristics. Although azithromycin can inﬂuence 
cardiac conduction, adverse consequences are largely 
confined to patients with established cardiac disease. So 
the cardiovascular safety of azithromycin in children and 
adults is unknown. A recent large retrospective review of 
data from Korea suggests that the risk of QT prolonga-
tion is greatest in elderly adults aged 60–79 years.17 Mean-
while, increased risk of infantile hypertrophic pyloric 
stenosis (IHPS) in infants has been reported.18–21
There is currently insufficient safety information on 
azithromycin treatment in children. A systematic review 
about the use and safety of azithromycin in neonates 
identified only 11 articles.22 The systematic review indi-
cated that azithromycin significantly reduces the risk of 
bronchopulmonary dysplasia(BPD) in preterm neonates. 
Adverse events (AEs) were mainly respiratory, neurolog-
ical and gastrointestinal but this was probably related to 
the patient population of sick neonates. There were four 
cases of infantile hypertrophic pyloric stenosis(IHPS) 
and the relationship between azithromycin and IHPS 
requires further investigation.21 Therefore, this system-
atic review aims to evaluate all published data and reports 
on the safety of the drug in children. The systematic 
review will aim to answer the following questions:
1. What are the rates and categories of azithromycin ad-
verse drug reactions (ADRs) in children? Are ADRs 
different in children aged 1–59 months? Are ADRs dif-
ferent following MDA?
2. Do cardiovascular events occur in paediatric patients? 
If so, is there a subgroup of paediatric patients for 
whom the incidence of cardiovascular events is high-
er?
3. Do the rates and categories of ADRsvary with dose in 
children? If so, are there dose-related ADRs?
MEthOds
This review will be carried out as Preferred Reporting 
Items for Systematic Reviews (PRISMA) and Meta-anal-
yses guidelines.23 24 This protocol has been registered 
in the international prospective register of systematic 
reviews.
search strategy
Selection criteria will use the Population, Intervention, 
Comparison, Outcome, Study design to determine the 
eligibility of articles. No limitation on language and year 
of publication will be set.
Population
We will include all paediatric patients aged from 0 to 18 
years. We will analyse paediatric patients aged from 1 to 
59 months as a subset. There will be no limitation on 
medical condition or indication.
Intervention
Azithromycin given either as periodic MDA at intervals 
up to 12 months or as a therapeutic agent.
Comparison
Placebo. Other antibiotics or no comparison.
Outcome
The incidence and category of ADRs (especially cardi-
ovascular safety; eg, cardiac arrhythmia or a prolonged 
QT-time, or pyloric stenosis) in paediatric patients.
Study design
In the systematic review, we will include all types of studies, 
including randomised controlled trials (RCTs), cohort 
studies, case–control studies, cross-sectional studies, case 
series and case reports. Only peer-reviewed publications 
will be included. We will exclude editorials, conference 
abstracts and reviews. Studies that include both the chil-
dren and adults will be excluded if they do not separate 
the data. We will also review ADR reports from pharma-
covigilance systems.
search strategy
MEDLINE, PubMed, Cochrane Central Register of 
Controlled Trials, Embase, CINAHL and International 
Pharmaceutical Abstracts will be searched. All searches 
will be from the beginning of the database until February 
2019 and all languages will be included. The search 
strategy will be developed based on the instructions in 
Cochrane handbook for systematic reviews of interven-
tions and will be specific for each database.23 The search 
strategy will include a combination of the medical subject 
headings and free text terms for azithromycin and 
neonates, infants and children (online supplementary 
appendix 1). We will look for additional studies in the 
reference lists of selected articles and contact authors for 
unclear information.
We will also search ADR spontaneous reporting systems 
to include: (1) warnings issued; (2) case reports of ADRs 
to azithromycin in children reported and (3) signal 
detection studies performed.
study records
The studies will initially be independently selected by two 
reviewers (WYL and XCP, students) on reading of the 
title and abstract of the articles. Once relevant articles 
are screened in, a complete analysis of the full-text arti-
cles will be performed by the previously defined selection 
criteria. Any disagreements will be resolved by discus-
sion with a third reviewer (LNZ, a trained pharmacist) 
if needed.
risk of bias in individual studies
The RCTs will be assessed using Cochrane risk of bias 
tool for assessing the risk of bias while case–control and 
cohort studies using Newcastle-Ottawa Scale.25 26 The 
case series and case reports will be assessed using The 
Joanna Briggs Institute Critical Appraisal tools.27 No 
quality assessment will be done for reports from the ADR 
monitoring system.
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data extraction
Data will be extracted from all included studies using 
specifically developed data extraction forms. Extracted 
information will contain: (1) the article metadata, 
including authors’ name, principal author’s country, and 
study setting and purpose; (2) method (study design and 
information of study quality according to quality assess-
ment criteria of different types of studies); (3) partici-
pant and setting (sample size, age, gender composition, 
inclusion criteria, diagnostic criteria and setting); (4) 
intervention (medicine, route and dose); (5) outcomes 
(type and severity of ADRs); (6) conclusion (authors’ 
conclusion on safety evaluation) and (7) confirmation of 
eligibility for review.
For continuous data, mean, SD and number of partic-
ipants will be extracted. For categorical data, events 
and total number of participants will be extracted. 
Whenever possible, we will use the results from an 
intention-to-treat analysis. If necessary, the author of 
the included studies will be contacted to gather rele-
vant information.
WHO—Uppsala Monitoring Centre system will be 
adopted to evaluate the relevance of suspected ADRs and 
azithromycin in case reports.28
data analysis and synthesis
Data synthesis
Relative risks (RRs) will be measured in RCTs and cohort 
studies, odds ratios (ORs) in case–control studies and 
reporting ORs in ADR spontaneous reporting systems.29 
The RRs of ADRs present in at least two RCTs and cohort 
studies will be calculated, and only the RR>1 with at 
least three cases will be included suggesting that more 
ADRs will be associated with azithromycin. Meta-analysis 
will be carried out in Revman, if possible. RRs and 95% 
CIs will be estimated for each RCT. The heterogeneity 
will be assessed using the χ2 test, and further quantified 
using the I2. The data will be considered homogeneous 
if I2≤50%. Fixed effects models will be used to produce 
summary RRs and 95% CIs where heterogeneity did not 
exist. If statistical heterogeneity did exist then random 
effects models will be applied.
Logistic regression models will be used to identify 
univariable and multivariable risk factors for AEs. We 
will include all significant variables in univariable logistic 
regression analysis. The multivariate analysis will be 
performed with the variables with p<0.05 (p<0.05 will be 
considered to be statistically significant) and calculate 
the OR and 95% CI of the study factors. All significant 
variables are as follows: (1) age; (2) sex; (3) body weight; 
(4) administration route; (5) rationality of indication; 
(6) rationality of dose and (7) rationality of course of 
treatment.
Subgroup analyses
Subgroup analysis will be performed on different age 
groups and different dosage of azithromycin.
setting and participants
Patients and the public were not involved in the develop-
ment of this protocol.
EthICs And dIssEMInAtIOn
The results of this systematic review will be disseminated 
through the publication of papers in peer-reviewed jour-
nals. Our findings should be of benefit to both health 
professionals, who prescribe azithromycin, and patients, 
who receive azithromycin.
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